Evaluation of efficacy and safety of romosozumab administration group and ibandronate sodium hydrate administration group for osteoporosis patients after denosumab treatment - Evaluation of efficacy and safety of romosozumab administration group and ibandronate sodium hydrate administration group for osteoporosis patients after denosumab treatment

Shinshu University School of Medicine Dept. of Orthopaedic Surgery0 个研究点目标入组 60 人开始时间: 2019年7月17日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. If you had previously been treated with romosozumab, ibandronate sodium hydrate 2. If you are allergic to romosozumab, ibandronate sodium hydrate 3. Those who have hypocalcemia 4. For pregnant women or women who are nursing 5.Patients with disorders that delay esophageal passage such as esophageal stricture or achalasia 6.Patients who can not keep standing or sitting for more than 60 minutes when taking 7. Those with severe renal dysfunction (eGFR 30 ml / min / less than 1.73 m2) or those receiving dialysis 8.Patients with upper digestive tract disorder such as dysphagia, esophagitis, gastritis, duodenitis, ulcer etc. 9. Other patients who the research director judged inappropriate as a subject

发起方

Shinshu University School of Medicine Dept. of Orthopaedic Surgery